drugset / Trial / NCT04765228
Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
A prospective one-arm study of pegylated liposomal doxorubicin combined with anlotinib for neoadjuvant treatment of locally advanced soft tissue sarcoma.
Timeline
- Start
- 2020-04-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |